Steminent Biotherapeutics (ROCO:7729) Total Payout Ratio: 4.50 (As of Sep. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7729 Steminent Biotherapeutics Inc ROCO:7729
19 GF Score
Price NT$114.50
! 5 Warning Signs
View Full Analysis

What is Steminent Biotherapeutics Total Payout Ratio?

Steminent Biotherapeutics ROCO:7729 -2.55% 19 Total Payout Ratio is 4.50 as of Sep. 13, 2026. GuruFocus rates ROCO:7729 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Steminent Biotherapeutics's current Total Payout Ratio is 4.50.

Steminent Biotherapeutics Total Payout Ratio Related Terms

Steminent Biotherapeutics Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Steminent Biotherapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steminent Biotherapeutics Total Payout Ratio Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial 2.03 0.02 3.48 0.03 2.35

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.01 0.05 0.02 4.35 4.61

ROCO:7729 vs VRTX, REGN, MRNA: Total Payout Ratio Comparison

For the Biotechnology subindustry, Steminent Biotherapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Steminent Biotherapeutics Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Steminent Biotherapeutics's Total Payout Ratio falls into.


ROCO:7729
19GF Score
Steminent Biotherapeutics Inc ROCO:7729
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Steminent Biotherapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Steminent Biotherapeutics's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 408.97 + 0) / -174.147
=2.35

Steminent Biotherapeutics's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 512.172 + 0) / -111.035
=4.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 4.50 mean?
Steminent Biotherapeutics (ROCO:7729) has a Total Payout Ratio of 4.50 as of Sep. 13, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Steminent Biotherapeutics and its competitors.
Is Steminent Biotherapeutics' Total Payout Ratio too high?
Steminent Biotherapeutics' current Total Payout Ratio is 4.50. Overall, Steminent Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' Total Payout Ratio compare to VRTX and REGN?
Steminent Biotherapeutics' Total Payout Ratio of 4.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Steminent Biotherapeutics and its competitors. Steminent Biotherapeutics's current Total Payout Ratio is 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current Total Payout Ratio of 4.50. The current Total Payout Ratio is 4.50. Steminent Biotherapeutics' overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current Total Payout Ratio is 4.50 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Steminent Biotherapeutics Business Description

Address No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
19GF Score

Get the complete analysis for ROCO:7729

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$114.50
Price